Mural Oncology Newsroom

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its ARTISTRY-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

GlobeNewswireNov 21 05:15

Express News | Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its Artistry-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for Immunotherapy of Cancer

BreakingsNov 21 05:15

Morgan Stanley Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $13

Futu NewsNov 14 20:31 · Ratings

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)

TipRanksNov 14 20:00 · Ratings

Mural Oncology Analyst Ratings

BenzingaNov 14 17:48 · Ratings

Express News | Mural Oncology PLC Files for Mixed Shelf Offering of up to $300 Mln- SEC Filing

BreakingsNov 14 05:08

H.C. Wainwright Maintains Mural Oncology(MURA.US) With Buy Rating, Maintains Target Price $18

Futu NewsNov 14 01:31 · Ratings

Promising Developments in Mural Oncology Plc's Pipeline Reinforce Buy Rating

TipRanksNov 14 00:56 · Ratings

Mural Oncology Q3 2024 GAAP EPS $(1.87) Beats $(1.98) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $175.5M Are Expected To Fund Its Operations Into The Fourth Quarter Of 2025

BenzingaNov 13 20:12

Mural Oncology | 10-Q: Q3 2024 Earnings Report

SECNov 13 20:08 · Announcements

Mural Oncology | 8-K: Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

SECNov 13 20:08

Express News | Mural Oncology PLC: Reiterates Guidance on Projected Cash Runway Into Q4 2025

BreakingsNov 13 20:03

Mural Oncology 3Q Loss/Shr $1.87 >MURA

Dow JonesNov 13 20:02

Mural Oncology 3Q Research and Development Expenses $27.6M >MURA

Dow JonesNov 13 20:02

Express News | Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

BreakingsNov 13 20:00

Press Release: Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Dow JonesNov 13 20:00

Mural Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswireNov 11 20:00

Mural Oncology Presents Data Across Its Pipeline At 39th SITC Annual Meeting

BenzingaNov 8 06:21

Mural Oncology Price Target Announced at $18.00/Share by HC Wainwright & Co.

Dow JonesOct 17 19:09 · Ratings

Express News | Mural Oncology PLC : H.c. Wainwright Initiates Coverage With Buy Rating

BreakingsOct 17 18:04